2023
DOI: 10.1007/s10096-023-04577-x
|View full text |Cite
|
Sign up to set email alerts
|

Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
11
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 29 publications
0
11
0
Order By: Relevance
“…This study did not find any statistically significant differences in prognosis between monotherapy and combination therapy with CAZ/AVI for pulmonary CRKP infections, which may be due to the favorable tissue distribution of CAZ/AVI in airway epithelial cells [ 19 ], consistent with the results of Tumbarello et al The use of CAZ/AVI in bloodstream infections was found to be associated with better prognosis [ 20 ]. This study did not find any statistically significant differences in prognosis between monotherapy and combination therapy with CAZ/AVI for bloodstream CRKP infections, and recent studies have not found any significant effects of CAZ/AVI combination therapy on the prognosis of bloodstream CRKP infections [ 21 ]. Recent small-sample case studies have suggested that CAZ/AVI combination therapy is an effective treatment for central nervous system CRKP infections [ 22 ].…”
Section: Discussionmentioning
confidence: 52%
“…This study did not find any statistically significant differences in prognosis between monotherapy and combination therapy with CAZ/AVI for pulmonary CRKP infections, which may be due to the favorable tissue distribution of CAZ/AVI in airway epithelial cells [ 19 ], consistent with the results of Tumbarello et al The use of CAZ/AVI in bloodstream infections was found to be associated with better prognosis [ 20 ]. This study did not find any statistically significant differences in prognosis between monotherapy and combination therapy with CAZ/AVI for bloodstream CRKP infections, and recent studies have not found any significant effects of CAZ/AVI combination therapy on the prognosis of bloodstream CRKP infections [ 21 ]. Recent small-sample case studies have suggested that CAZ/AVI combination therapy is an effective treatment for central nervous system CRKP infections [ 22 ].…”
Section: Discussionmentioning
confidence: 52%
“…First, in the first wave of the pandemic, due to the severity of the SARS-CoV-2 infection, a higher proportion of deaths within the study occurred in the early stages of hospitalization; therefore, these patients had less time to develop superinfections and to obtain microbiological investigation results. In addition, the successful implementation of rapid diagnostics coupled with infectious counselling intervention for the timely and appropriate use of new drugs such as ceftazidime/avibactam and cefiderocol may suffice to counteract the putative positive influence of such infections on mortality [ 34 , 42 , 43 ].…”
Section: Discussionmentioning
confidence: 99%
“…In the light of the excellent clinical results obtained [ 3 9 ], the judicious prescription of ceftazidime/avibactam and the implementation of a surveillance system dedicated to resistance emergence detection should be aimed at. For the time being, KPC-Kp resistance to ceftazidime/avibactam is not perceived as a problem at scale, being deemed a rather uncommon phenomenon [ 11 ].…”
Section: Discussionmentioning
confidence: 99%
“…The alert issued in Italy based on data from 2014–2017 highlighted the endemic burden of KPC-Kp often characterized by a relevant number of bloodstream infections (BSIs) and endangering patient safety [ 2 ]. In 2018, the novel β-lactam/β-lactamase inhibitor combination ceftazidime/avibactam was introduced into clinical practice having shown excellent clinical activity against KPC-Kp [ 3 9 ]. More recently, it has been reported as the only independent survival predictor among KPC-Kp BSI patients [ 6 , 9 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation